Zai Lab Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zai Lab Ltd.
Initial public offerings by Norbert Bischofberger’s start-up as well as Spruce Biosciences and Shattuck Labs bring the US total to 65 in 2020. Also, the pipeline of health care SPACs is growing, Everest and Genor went public in Hong Kong, Idorsia leads recent follow-on offerings and Corbus cuts jobs.
From AI-assisted drug discovery to oncotherapy development, China has seen investment pour in over the past week, while the nation's largest online pharmacy is readying for a big Hong Kong debut.
Public Company Edition: Outside the US, Zai Lab raised more in its recent Hong Kong initial public offering – $766.4m – than PMV, Prelude, Taysha, Graybug and Greenwich combined. Also, Gilead priced debt to fund its $21bn Immunomedics buy and ADC Therapeutics raised $204m.
During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.
- Other Names / Subsidiaries
- Zai Lab Limited
- Zai Lab (Shanghai) Co., Ltd.